NSCLC patients who stopped immunotherapy due to side effects still showed lasting disease control and survival benefits..

Patients who discontinued cancer immunotherapy because of immune-related adverse events (irAEs) often had durable benefits ...

Small Cell Lung Cancer Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of ...

Lung cancer (LC) is a major global health issue, with high mortality rates and limited therapeutic options. It is primarily categorized into non-small cell lung cancer (NSCLC) and small cell lung ...

A new study published in The Annals of Thoracic Surgery suggests that Medicaid expansion under the Affordable Care Act has ...

Helene Duhamel had a very public fight with cancer after she was diagnosed with Hodgkin’s Disease back in 1992 while working ...

Lung cancer (LC) is a major global health issue, with high mortality rates and limited therapeutic options. It is primarily categorized into non-small ...

2024 — Researchers have demonstrated that patients with metastatic non-squamous non-small cell lung cancer (NSCLC) harboring specific mutations in the STK11 and/or KEAP1 tumor suppressor genes ...

Most patients who enroll in the Lung-MAP precision medicine trial in non-small cell lung cancer can now be matched to a targeted investigational treatment based on the results of their prior genomic ...

The study advanced beyond a one-size-fits-all model by developing both a global XGBoost classifier and cancer-type-specific ...

A common malaria drug could be repurposed to treat a variety of hematologic cancers and solid tumors, according to early ...

Tarlatamab is a bispecific T-cell engager that binds to DLL3 expressed on the surface of tumor cells and CD3 expressed on the surface of T-cells.